MDACC Study No:2013-0971 ( NCT No: NCT02040506)
Title:A Phase I, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Principal Investigator:Jorge Cortes
Treatment Agent:IGN523
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of IGN523 that can be given to patients with relapsed or refractory AML. The
safety of this drug will also be studied.

This is the first study using IGN523 in humans.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:IGN523
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Igenica Biotherapeutics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults